EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cosmecca Korea Co. Ltd (241710) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Cosmecca Korea Co. Ltd KRW 89,348, price KRW 127,300, upside -29.8%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Consumer Defensive · KR · ISIN KR7241710003

CK Thin data Sep 24, 2026

Cosmecca Korea Co. Ltd

241710 · KQ

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value 89,348 KRW · Overvalued (−30%)
!Quality 53/100
!Expensive Growth (revenue 5y +13.6 %/yr)
!Thin margins · 7.8% net margin (TTM)
!Low debt · negative free cash flow
·0.29% dividend yield
!Mixed vs. peers (5/9)
!Moderate moat 59/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 6 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

153,900 KRW 6,478 KRW Fair Value 89,348 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 6,478 KRW – 153,900 KRW · fair‑value band 67,011 KRW – 111,685 KRW · the 127,300 KRW price screens above the 89,348 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Cosmecca Korea Co. in your weekly email

Every Wednesday you see whether Cosmecca Korea Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cosmecca Korea Co., Ltd. engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.

Show more

Cosmecca Korea Co., Ltd. engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally. It offers skincare products, including lotion/toner, cream, essence, cleansers, Korean herbal products, mask sheet, scalp care, home scents, body and bath, exfoliators, and treatment products, as well as products for men, babies, and children; functional skincare products, which includes brightening, wrinkle and fine line, UV blocks/sunscreen, tanning, multi-functional, hair and body, and acne care products; and makeup products, such as BB and CC cream, skin cover balms, makeup base, foundation, concealer, lipstick, mascara, eyeliner, eyeshadow, blush/highlighter, and powders. The company was incorporated in 1999 and is headquartered in Eumseong-eup, South Korea.

Stock analysis

Cosmecca Korea Co. Ltd (241710) currently trades at 127,300 KRW, while our model-based Fair Value estimate is 89,348 KRW, implying the stock looks roughly 42.5% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 98,338 KRW per share, and 2 of the 15 models we run sit above the 127,300 KRW price.

Bear case: the DCF Models group reads lowest at 10,976 KRW, and 13 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 67,011 KRW (bear) to 111,685 KRW (bull), the price of 127,300 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Consumer Defensive sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Cosmecca Korea Co. Ltd reported revenue of 641B KRW in FY2025 versus 396B KRW in FY2021, a compound +12.8%/yr. Reported net income was 45.4B KRW in FY2025, compounding +50.3%/yr from FY2021.

Key figures

Market cap 1.4T KRW (≈ $999M) · P/S ratio 1.17 · Dividend yield 0.3% · Net margin 7.1% · Return on equity 22.7% · Return on assets (EBIT) 8.7% · Operating margin 11.8% · Revenue (TTM) 708B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 107% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −14% fair-value upside, at −30%, 241710 screens richer than that median.

Fair Value models

Bear 67,011 KRW Fair Value 89,348 KRW Bull 111,685 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 7,650 KRW 10,976 KRW 16,537 KRW 76
EPV 59,995 KRW 67,675 KRW 74,075 KRW 74
ROIC Compounder 67,777 KRW 86,162 KRW 108,246 KRW 72
All 15 models by family
DCF Models
Owner Earnings 7,650 KRW 10,976 KRW 16,537 KRW 76
Earnings-Based
Graham-Dodd 28,932 KRW 164,491 KRW 228,634 KRW 63
Lynch FV 46,223 KRW 66,033 KRW 85,842 KRW 61
PEG = 1.0 46,223 KRW 66,033 KRW 85,842 KRW 57
EPV 59,995 KRW 67,675 KRW 74,075 KRW 74
Multiples
P/E Multiple 67,011 KRW 89,348 KRW 111,685 KRW 63
P/S Multiple 54,247 KRW 72,329 KRW 90,412 KRW 58
P/B Multiple 54,247 KRW 72,329 KRW 90,412 KRW 55
EV/EBIT 103,407 KRW 136,649 KRW 169,892 KRW 66
EV/EBITDA 95,015 KRW 125,461 KRW 155,906 KRW 67
EV/Revenue 66,691 KRW 93,697 KRW 120,702 KRW 54
Asset-Based
NCAV (Graham) 11,832 KRW 15,854 KRW 23,663 KRW 54
Economic Profit
Residual Income 24,263 KRW 32,110 KRW 89,405 KRW 67
ROIC Compounder 67,777 KRW 86,162 KRW 108,246 KRW 72
Growth Earnings
Growth-Adj P/E 68,837 KRW 98,338 KRW 127,840 KRW 67

Open the full fair value analysis →

Notify me when 241710 reaches fair value

Put 241710 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 53 · Market factors (momentum, volatility) 76

Profitability 55
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 24
Disciplined investing over empire-building
Low Volatility 31
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 86
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+22.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+77.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+76.9%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.56% vs 15%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 13%
2025 sits 104% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)

241710 screens 42% overvalued. Compare with Colgate-Palmolive Company →

Compare Cosmecca Korea Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 251 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −30% · Below median
Profitability
Return on equity (TTM) 23% · Top 25%
Return on assets 10% · Top 25%
Net margin (TTM) 8% · Above median
Operating margin (TTM) 12% · Above median
Growth and dividend
Revenue growth 56% · Top 25%
Dividend yield (TTM) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.12× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)100 · sector 5
PAST (return on equity)91 · sector 27
HEALTH (low debt)94 · sector 98
DIVIDEND (yield)6 · sector 55

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Colgate-Palmolive Company CL $85.93 $55.95 −35%
Hindustan Unilever Limited HINDUNILVR ₹1,950 ₹775.25 −60%
Kenvue Inc KVUE $17.86 $12.73 −29%
Kimberly-Clark Corporation KMB $97.70 $83.93 −14%
Henkel AG HEN €68.50 €80.96 +18%
The Estée Lauder Companies Inc EL $98.83 $27.22 −72%
Church & Dwight Co CHD $96.02 $65.12 −32%
Beiersdorf Aktiengesellschaft, BEI €78.18 €68.95 −12%
Puig Brands, S.A PUIG €17.56 €19.32 +10%
The Clorox Company CLX $87.15 $104.53 +20%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Cosmecca Korea Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/241710

Frequently asked questions

Is Cosmecca Korea Co. Ltd (241710) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 89,348 KRW versus a price of 127,300 KRW, about −30% upside (overvalued).
What is the fair value of 241710?
Our model-based fair value for Cosmecca Korea Co. Ltd is 89,348 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 127,300 KRW.
What is the quality score of 241710?
Cosmecca Korea Co. Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cosmecca Korea Co. Ltd (241710)?
Our model-based price target is the fair value of 89,348 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 67,011 KRW, optimistic scenario 111,685 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Cosmecca Korea Co. Ltd stock forecast for 2026?
Our models put fair value at 89,348 KRW, about −30% upside versus a price of 127,300 KRW (overvalued). Cautious scenario 67,011 KRW, optimistic scenario 111,685 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Cosmecca Korea Co. Ltd (241710)?
Cosmecca Korea Co. Ltd reported trailing-twelve-month revenue of about 708B KRW (latest available figure, as of Sep 24, 2026).
Does Cosmecca Korea Co. Ltd pay a dividend?
Cosmecca Korea Co. Ltd currently shows a dividend yield of about 0.29% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Cosmecca Korea Co. Ltd (241710)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cosmecca Korea Co. Ltd it is 89,348 KRW per share (as of Sep 24, 2026), against a price of 127,300 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Cosmecca Korea Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 241710 trades above its calculated fair value: price 127,300 KRW, fair value 89,348 KRW, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 241710?
No. The price is what the market pays today (127,300 KRW); the fair value is what the company's own numbers justify (89,348 KRW). For Cosmecca Korea Co. Ltd the two are 37,952 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Cosmecca Korea Co. Ltd worth?
The market values Cosmecca Korea Co. Ltd at about 1.4T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 127,300 KRW; our models calculate a fair value of 89,348 KRW per share.
What do the bullish and bearish scenarios say about 241710?
Our models span a range for Cosmecca Korea Co. Ltd: cautious scenario 67,011 KRW, base 89,348 KRW, optimistic 111,685 KRW per share (as of Sep 24, 2026, price 127,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cosmecca Korea Co. Ltd (241710)?
Balance-sheet figures for Cosmecca Korea Co. Ltd (as of Sep 24, 2026): return on equity 22.7%, debt of 0.12 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 241710 from its 52-week high?
Cosmecca Korea Co. Ltd trades at 127,300 KRW, about 17% below its 52-week high of 153,900 KRW and 107% above the low of 61,405 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 89,348 KRW is for.
Which stocks are comparable to Cosmecca Korea Co. Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cosmecca Korea Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 127,300 KRW, calculated fair value 89,348 KRW (−30%), Quality Score 53/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 241710 calculated?
We run Cosmecca Korea Co. Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 89,348 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Cosmecca Korea Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cosmecca Korea Co. Ltd (241710)?
The closing price on Sep 23, 2026 was 127,300 KRW. Our model-based fair value is 89,348 KRW, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cosmecca Korea Co. Ltd right now?
The price sits above even our optimistic bull case (111,685 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cosmecca Korea Co. Ltd

How large is the market capitalisation of Cosmecca Korea Co. Ltd (241710)?
The market capitalisation of Cosmecca Korea Co. Ltd is 1.4T KRW (≈ $999M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cosmecca Korea Co. Ltd (241710)?
The price-to-sales ratio of Cosmecca Korea Co. Ltd is 1.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Cosmecca Korea Co. Ltd (241710)?
The dividend yield of Cosmecca Korea Co. Ltd is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cosmecca Korea Co. Ltd (241710)?
The net margin of Cosmecca Korea Co. Ltd is 7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cosmecca Korea Co. Ltd (241710)?
The return on equity (ROE) of Cosmecca Korea Co. Ltd is 22.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cosmecca Korea Co. Ltd (241710)?
On an EBIT basis the return on assets of Cosmecca Korea Co. Ltd is 8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cosmecca Korea Co. Ltd (241710)?
The operating margin of Cosmecca Korea Co. Ltd is 11.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cosmecca Korea Co. Ltd (241710)?
Revenue at Cosmecca Korea Co. Ltd is growing +56.4% versus a year earlier (3y avg +17.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cosmecca Korea Co. Ltd (241710)?
Earnings per share at Cosmecca Korea Co. Ltd are growing +127% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cosmecca Korea Co. Ltd (241710) generate?
The free cash flow of Cosmecca Korea Co. Ltd is −6.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cosmecca Korea Co. Ltd (241710) carry?
The net debt of Cosmecca Korea Co. Ltd is 96.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cosmecca Korea Co. Ltd in the live analysis

One click puts Cosmecca Korea Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.